株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

in-situハイブリダイゼーション (ISH) の世界市場予測 2021年:FISH・CISH・癌診断・細胞学・神経科学・免疫学・感染症

In situ Hybridization Market by Technique (FISH, CISH), Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic And Research Institutions) - Global Forecast to 2021

発行 MarketsandMarkets 商品コード 338073
出版日 ページ情報 英文 194 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
in-situハイブリダイゼーション (ISH) の世界市場予測 2021年:FISH・CISH・癌診断・細胞学・神経科学・免疫学・感染症 In situ Hybridization Market by Technique (FISH, CISH), Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic And Research Institutions) - Global Forecast to 2021
出版日: 2017年01月18日 ページ情報: 英文 194 Pages
概要

世界のin-situハイブリダイゼーション (ISH) 市場規模は、2016年から2021年にかけて5.8%のCAGR (年間複合成長率) で推移し、2016年の5億5,710万米ドルから2021年までに7億3,990万米ドルに達すると予測されています。

当レポートでは、世界のin-situハイブリダイゼーション (ISH) 市場ついて調査し、市場概要、市場への各種影響因子および市場機会の分析、市場全体およびアプリケーション・エンドユーザー・地域別の市場動向と市場成長予測、競合環境、および主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

  • 促進因子
  • 抑制因子
  • 機会

第5章 技法別

  • FISH
    • DNA-FISH
    • RNA-FISH
  • CISH

第6章 アプリケーション別

  • 癌診断
  • 細胞学
  • 神経科学
  • 免疫学
  • 感染症

第7章 エンドユーザー別

  • 分子診断ラボ
  • 大学 & 研究機関
  • CRO
  • 医薬品 & バイオテクノロジー企業

第8章 地域分析

  • 北米
  • 欧州
  • アジア
  • その他 (RoW)

第9章 市場シェア分析

  • ABBOTT (米国)
  • ROCHE DIAGNOSTICS (スイス)
  • LEICA BIOSYSTEMS NUSSLOCH GMBH (ドイツ)
  • AGILENT TECHNOLOGIES (米国)

第10章 競合情勢

  • 合意、コラボレーション、提携
  • 新製品発売
  • 拡大
  • 買収
  • その他

第11章 企業プロファイル

  • ABBOTT
  • ROCHE DIAGNOSTICS
  • LEICA BIOSYSTEMS NUSSLOCH GMBH
  • AGILENT TECHNOLOGIES

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 3649

"The in situ hybridization market is projected to reach USD 739.9 million by 2021 from USD 557.1 million in 2016, at a CAGR of 5.8% in the next five years (2016 to 2021)."

Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are some factors expected to drive the growth of the global in situ hybridization market in the coming years.

In 2016, North America is expected to account for the largest share of the global in situ hybridization market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of companion diagnostics is attributed to the development and launch of newer therapeutic agents.

In the coming years, the in situ hybridization market is expected to witness the highest growth in the Asia-Pacific region, with emphasis on India, China, and Japan. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.

The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies [agreements, partnerships, collaborations, product launches, acquisitions, and expansions; and other strategies (including approvals, product enhancements, and product deployments] to increase their market shares and establish a strong foothold in the global market.

In-depth interviews were conducted with CEOs, Sales and Marketing Directors, other innovation and technology directors, and executives from various key organizations operating in the adaptive security market place.

  • By Company Type: Tier 1: 50%, Tier 2: 42%, Tier 3: 8%
  • By Designation: Director Level: 58%, C-Level: 25%, Others: 17%
  • By Region: North America: 46%, Europe: 31%, APAC: 15%, ROW: 8%

The report includes the study of key players offering in situ hybridization technique such as Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.)

Research Coverage:

The focus of this report is on providing quantitative information for clients seeking market size information on various segments of the In Situ Hybridization market. It provides the current and forecast assessment of the Global In Situ Hybridization market. The report incorporates various segments such as by technique, application, end-user and regional analysis. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their market shares, company profiles, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the products and services offered by top players in the telehealth market. The report analyzes the in situ hybridization market by component, mode of delivery, and end user.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the in situ hybridization market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for in situ hybridization across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the in situ hybridization market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the in situ hybridization market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
    • 2.2.2. PRIMARY RESEARCH
    • 2.2.3. KEY INDUSTRY INSIGHTS
  • 2.3. KEY DATA FROM PRIMARY SOURCES
  • 2.4. KEY INSIGHTS FROM PRIMARY SOURCES
  • 2.5. MARKET SIZE ESTIMATION METHODOLOGY
    • 2.5.1. RESEARCH DESIGN
  • 2.6. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.7. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. MARKET OVERVIEW

  • 4.1. INTRODUCTION
  • 4.2. MARKET DYNAMICS
    • 4.2.1. DRIVERS
    • 4.2.2. RESTAINTS/CHALLENGES
    • 4.2.3. OPPORTUNITIES

5. IN SITU HYBRIDIZATION MARKET, BY TECHNIQUE

  • 5.1. INTRODUCTION
  • 5.2. FLUORESCENCE IN SITU HYBRIDIZATION MARKET (FISH)
    • 5.2.1. DNA-FISH
    • 5.2.2. RNA-FISH
  • 5.3. CHROMOGENIC IN SITU HYBRIDIZATION MARKET (CISH)

6. IN SITU HYBRIDIZATION MARKET, BY APPLICATION

  • 6.1. INTRODUCTION
  • 6.2. CANCER DIAGNOSIS
  • 6.3. IMMUNOLOGY
  • 6.4. NEUROSCIENCE
  • 6.5. CYTOLOGY
  • 6.6. INFECTIOUS DISEASES

7. IN SITU HYBRIDIZATION MARKET, BY END-USER

  • 7.1. INTRODUCTION
  • 7.2. MOLECULAR DIAGNOSTIC LABORATORIES
  • 7.3. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 7.4. CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 7.5. ACADEMIC & RESEARCH INSTITUTIONS

8. IN SITU HYBRIDIZATION MARKET, BY REGION

  • 8.1. INTRODUCTION
  • 8.2. NORTH AMERICA
    • 8.2.1. U.S.
    • 8.2.2. CANADA
  • 8.3. EUROPE
    • 8.3.1. EU5- (U.K, GERMANY, FRANCE, SPAIN & ITALY)
    • 8.3.2. REST OF EUROPE (ROE)
  • 8.4. ASIA-PACIFIC
  • 8.5. REST OF THE WORLD

(Consolidated Market Numbers for Latin America, Middle-East and Africa Will Be Provided)

9. COMPETITIVE LANDSCAPE

  • 9.1. OVERVIEW
  • 9.2. COMPETITIVE SITUATION AND TRENDS
    • 9.2.1. APPROVALS
    • 9.2.2. PRODUCT DEPLOYMENTS
    • 9.2.3. NEW PRODUCT LAUNCHES
    • 9.2.4. OTHERS (IF ANY)

10. COMPANY PROFILES#

  • 10.1. INTRODUCTION
  • 10.2. ABBOTT LABORATORIES, INC.
    • 10.2.1. BUSINESS OVERVIEW
    • 10.2.2. FINANCIAL OVERVIEW
    • 10.2.3. PRODUCT OFFERINGS
    • 10.2.4. RECENT DEVELOPMENTS
  • 10.3. F.HOFFMANN-LA ROCHE LTD.
  • 10.4. THERMOFISHER SCIENTIFIC, INC.
  • 10.5. MERCK KGAA
  • 10.6. AGILENT TECHNOLOGIES, INC.
  • 10.7. PERKIN ELMER, INC.
  • 10.8. DANAHER CORPORATION / LEICA BIOSYSTEMS NUSSLOCH GMBH
  • 10.9. EXIQON A/S
  • 10.10. BIOGENEX LABORATORIES, INC.
  • 10.11. ADVANCED CELL DIAGNOSTICS, INC
  • 10.12. BIO SB, INC.

LIST OF TABLES

  • TABLE 1: GLOBAL IN SITU HYBRIDIZATION MARKET, BY REGION/COUNTRY, 2016 (USD MILLION)
  • TABLE 2: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 3: GLOBAL FISH MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 4: NORTH AMERICA: FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 5: EUROPE: FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 6: GLOBAL DNA-FISH MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 7: NORTH AMERICA: DNA-FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 8: EUROPE: DNA-FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 9: GLOBAL RNA-FISH MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 10: NORTH AMERICA: RNA-FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 11: EUROPE: RNA-FISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 12: GLOBAL CISH MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: NORTH AMERICA: CISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 14: EUROPE: CISH MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 15: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 16: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR CANCER DIAGNOSIS, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 17: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR CYTOLOGY, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 18: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR NEUROSCIENCE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 19: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR IMMUNOLOGY, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 20: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 21: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 22: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR MOLECULAR DIAGNOSTIC LABORATORIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE FOR MOLECULAR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 24: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE FOR MOLECULAR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 25: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 26: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2014 - 2021 (USD MILLION)
  • TABLE 27: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 28: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2014 - 2021 (USD MILLION)
  • TABLE 29: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2014 - 2021 (USD MILLION)
  • TABLE 30: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 31: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 32: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 33: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 34: GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 35: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 36: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 37: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 38: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 39: U.S.: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 40: U.S.: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 41: U.S.: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 42: CANADA: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 43: CANADA: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 44: CANADA: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 45: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 46: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 47: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 48: EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 49: EU-5: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 50: EU-5: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 51: EU-5: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 52: REST OF EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 53: REST OF EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 54: REST OF EUROPE: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 55: ASIA-PACIFIC: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 56: ASIA-PACIFIC: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 57: ASIA-PACIFIC: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 58: ROW: IN SITU HYBRIDIZATION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 59: ROW: IN SITU HYBRIDIZATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 60: ROW: IN SITU HYBRIDIZATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: MARKET SIZE ESTIMATION - USD VALUE
  • FIGURE 2: MARKET SIZING - (USD VALUE ANALYSIS)
  • FIGURE 3: COMPETITIVE ASSESSMENT
  • FIGURE 4: RESEARCH DESIGN
  • FIGURE 5: DATA TRIANGULATION
  • FIGURE 6: GLOBAL IN SITU HYBRIDIZATION MARKET, BY TECHNIQUE, 2016 (USD MILLION)
  • FIGURE 7: GLOBAL IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2016 (USD MILLION)
  • FIGURE 8: GLOBAL IN SITU HYBRIDIZATION MARKET, BY END USER, 2016 (USD MILLION)
  • FIGURE 9: MARKET OVERVIEW
  • FIGURE 10: IN SITU HYBRIDIZATION MARKET SEGMENTATION, BY TECHNIQUE
  • FIGURE 11: THE FISH TECHNIQUE SEGMENT IS EXPECTED TO DOMINATE THE IN SITU HYBRIDIZATION MARKET IN 2016
  • FIGURE 12: IN SITU HYBRIDIZATION MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 13: CANCER DIAGNOSIS SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: TIMELINE OF FDA APPROVALS FOR KEY FISH-BASED COMPANION DIAGNOSTICS IN ONCOLOGY
  • FIGURE 15: IN SITU HYBRIDIZATION MARKET SEGMENTATION, BY END USER
  • FIGURE 16: MOLECULAR DIAGNOSTIC LABORATORIES DOMINATE THE IN SITU HYBRIDIZATION MARKET, BY END USER (2016)
  • FIGURE 17: MARKET SHARE ANALYSIS
  • FIGURE 18: SHARE OF KEY STRATEGIES (2013-2016)
  • FIGURE 19: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS (2013-2016)
  • FIGURE 20: PRODUCT LAUNCHES (2013-2016)
  • FIGURE 21: EXPANSIONS (2013-2016)
  • FIGURE 22: ACQUISITIONS (2013-2016)
  • FIGURE 23: OTHER STRATEGIES (2013-2016)
  • FIGURE 24: ROUTE TO GROWTH: ORGANIC VS. INORGANIC STRATEGIES
  • FIGURE 25: ORGANIC GROWTH STRATEGIES
  • FIGURE 26: INORGANIC GROWTH STRATEGIES
Back to Top